Duvic M - Search Results

1

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.

Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. Senff NJ, et al. Among authors: duvic m. Blood. 2008 Sep 1;112(5):1600-9. doi: 10.1182/blood-2008-04-152850. Epub 2008 Jun 20. Blood. 2008. PMID: 18567836 Free article. Review.

2

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion.

Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Jackow CM, et al. Among authors: duvic m. Blood. 1997 Jan 1;89(1):32-40. Blood. 1997. PMID: 8978274 Free article.

3

The role for interleukin-12 therapy of cutaneous T cell lymphoma.

Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML. Rook AH, et al. Among authors: duvic m. Ann N Y Acad Sci. 2001 Sep;941:177-84. doi: 10.1111/j.1749-6632.2001.tb03721.x. Ann N Y Acad Sci. 2001. PMID: 11594571 Clinical Trial.

4

Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective.

Duvic M. Duvic M. Clin Lymphoma. 2000 Nov;1 Suppl 1:S15-20. doi: 10.3816/clm.2000.s.003. Clin Lymphoma. 2000. PMID: 11707858 Review.

5

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.

Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, Olsen E, Pittelkow M, Russell-Jones R, Takigawa M, Willemze R; ISCL. Vonderheid EC, et al. Among authors: duvic m. J Am Acad Dermatol. 2002 Jan;46(1):95-106. doi: 10.1067/mjd.2002.118538. J Am Acad Dermatol. 2002. PMID: 11756953 Review.

6

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.

Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Breneman D, et al. Among authors: duvic m. Arch Dermatol. 2002 Mar;138(3):325-32. doi: 10.1001/archderm.138.3.325. Arch Dermatol. 2002. PMID: 11902983 Clinical Trial.

7

Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).

Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Duvic M, et al. Clin Lymphoma. 2002 Mar;2(4):222-8. doi: 10.3816/clm.2002.n.003. Clin Lymphoma. 2002. PMID: 11970761 Clinical Trial.

8

Therapy options in cutaneous T-cell lymphoma.

Apisarnthanarax N, Duvic M. Apisarnthanarax N, et al. Among authors: duvic m. Expert Rev Anticancer Ther. 2001 Oct;1(3):403-20. doi: 10.1586/14737140.1.3.403. Expert Rev Anticancer Ther. 2001. PMID: 12113107 Review.

9

Primary cutaneous B-cell lymphoma.

Bogle MA, Riddle CC, Triana EM, Jones D, Duvic M. Bogle MA, et al. Among authors: duvic m. J Am Acad Dermatol. 2005 Sep;53(3):479-84. doi: 10.1016/j.jaad.2005.04.043. J Am Acad Dermatol. 2005. PMID: 16112357

10

Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.

Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S. Assaf C, et al. Among authors: duvic m. Br J Dermatol. 2006 Aug;155(2):261-6. doi: 10.1111/j.1365-2133.2006.07329.x. Br J Dermatol. 2006. PMID: 16882161 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

605 results

Search Page

Filters